Čeština | Dansk | Deutsch | English | Español | Français | Italiano | Nederlands | Norsk | Polski | Português | Pусский | Suomi | Svenska | US
Euro Huntington's disease network [logo]
EHDN2016 MALADIE RÉSEAU REGISTRY PROJECTS SE CONNECTER
 
 
  
Wet Biomarkers -
--->Nouvelles
[+]Projet
[-]Pays
--->[+]Autriche
--->[+]Belgique
--->[+]République Tchèque
--->[+]Danemark
--->[+]Finlande
--->[-]France
--->Coordination
--->Associations Huntington
--->Amiens
--->Bordeaux
--->[-]Clermont-Ferrand
--->[-]Documents
--->Informed Consent
--->ERB Template
--->ERB
--->Lille
--->[+]Rouen
--->Strasbourg
--->[+]Allemagne
--->[+]Ireland
--->[+]Italie
--->[+]Pays-Bas
--->[+]Norvège
--->[+]Pologne
--->[+]Portugal
--->[+]Russia
--->[+]Espagne
--->[+]Suède
--->[+]Suisse
--->[-]Royaume-Uni
--->Coordination
--->Associations Huntington
--->Links
--->[-]UKHDN
--->Member Sites
--->Activities
--->News
--->Meetings
--->Research prog
--->Documents
--->Standard of Care
--->Aberdeen
--->[+]Ayr
--->Belfast
--->Birmingham
--->[+]Blandford Forum
--->Bristol
--->Cambridge
--->Cardiff
--->Dundee
--->Edinburgh
--->Exeter
--->Fife
--->Forth Valley
--->Glasgow
--->Gloucester
--->Hull
--->Inverness
--->Launceston
--->Leeds
--->Leicester
--->Liverpool
--->London - Guy's Hospital
--->London - Hammersmith
--->London - NHNN
--->London - Royal Hospital
--->London - St. George´s
--->Manchester
--->Newcastle-Upon-Tyne
--->[+]Northampton
--->Nottingham
--->Oxford
--->[+]Plymouth
--->Poole
--->Preston
--->Reading
--->[+]Sheffield
--->Southampton
--->Stoke-on-Trent
--->Swindon
--->Wrexham
--->[+]Outside Europe
[-]Groupes de travail
--->[+]Advanced HD
--->[+]Behavioural Phenotype
--->[+]Biological Modifiers
--->[+]Biomarkers
--->[+]Brain and Tissue Banking
--->[+]Cognitive Phenotype
--->[+]Environmental Modifiers
--->[+]Functional Ability
--->[+]Genetic Testing
--->[-]Genetic Modifiers
--->[+]Dates
--->[-]Meetings
--->Meeting 2005/09
--->Meeting 2006/04
--->Meeting 2008/09
--->Meeting 2009/06
--->Meeting 2012/13
--->[+]Health Economics
--->[+]Imaging
--->[+]Juvenile HD
--->[+]Motor Phenotype
--->[+]Neuroprotective Therapy
--->[-]Physiotherapy
--->Dates
--->[-]Meetings
--->Meeting 2008/05
--->Meeting 2008/09
--->Meeting 2009
--->Meeting 2012
--->Meeting 2014
--->Meeting 2015
--->Meeting 2016
--->Call 2017 Subgroup Guide...
--->[+]Quality of Life
--->[+]Standard of Care
--->[+]Surgical Approaches
--->[+]Symptomatic Research
--->[+]Young Adults
[-]Evénements
--->[+]EHDN 2016
--->EHDN 2014
--->[-]EHDN 2012
--->Introduction
--->Announcement
--->Programme Fri
--->Programme Sat
--->Programme Sun
--->Additional Meetings
--->Important Dates
--->Registration
--->[+]Travel & Accommodation
--->[+]EHA Registration
--->EHA Programme
--->Reception Dinner
--->About Stockholm
--->[+]Abstract Submission
--->Reimbursement
--->[-]Documents
--->Handouts
--->Presentations
--->[-]Posters
--->Pathogenic mechanisms
--->Animal models
--->Choreatic disorders - no...
--->Genetic modifiers
--->Wet Biomarkers
--->Imaging
--->Clin characteristics
--->Clin char-motor
--->Clin char-cognitive
--->Clin char - behaviour
--->Clin char-other
--->Clinical studies
--->Genetic testing
--->Clinical care
--->Experimental Rx
--->Clinical Rx
--->Non-scientific
--->Contacts
--->Feedback & Evaluation
--->[+]EHDN 2010
--->[+]EHDN 2008
--->[+]EHDN 2007
--->[+]EHDN 2006
--->[+]EHDN 2005
--->[+]EHDN 2004
[+]Communication
--->Offres d'emploi
datedescriptiontailleauteur document 
03.08.26Selisistat: potential pharmacodynamic readouts based on transcriptomics32 kBanonymousapplication/mswordf04-potential-pharmacodynamic-readouts 
03.08.26Mutant Huntingtin fragmentation in immune cells tracks Huntington’s Disease progression32 kBanonymousapplication/mswordf05-mutant-huntingtin-fragmentation 
03.08.26Whole blood SAGE digital gene expression profiling from Huntington's disease patients32 kBanonymousapplication/mswordf03-blood-sage-digital-gene-expression 
03.08.26Selisistat: Soluble htt protein levels as a potential pharmacodynamic readout32 kBanonymousapplication/mswordf02-soluble-htt-protein-levels 
03.08.26Establishment of novel assays for quantification of full-length wild-type and mutant Huntingtin by using the AlphaLISA technology32 kBanonymousapplication/mswordf01-establishment-novel-assays 
03.08.26A critical evaluation of inflammatory markers in Huntington’s Disease plasma32 kBanonymousapplication/mswordf06-critical-evaluation-inflammatory-m... 
03.08.26Cross-sectional and longitudinal associations between CRP and neuropsychiatric symptoms in HD32 kBanonymousapplication/mswordf07-crp-neuropsychiatric-symptoms 
03.08.26Abnormal regulation of macrophage-derived transforming growth factor – β 1 (TGF-β1) production in Huntington Disease32 kBanonymousapplication/mswordf12-abnormal-regulation-of-macrophage 
03.08.268OHdG is not a biomarker for Huntington’s Disease; lessons for future biomarker studies32 kBanonymousapplication/mswordf14-8ohdg 
03.08.26Progredient deterioration of hepatic mitochondrial function in Huntington's Disease – measured by using the 13C-methionin breath test32 kBanonymousapplication/mswordf11-progredient-deterioration-hepatic-... 
03.08.26The study on molecular changes related to energy metabolism in Huntington’s disease subjects - looking for biomarkers32 kBanonymousapplication/mswordf09-molecular-changes-related-to-energ... 
03.08.26The autoimmune profile of Huntington`s Disease patients - a pilot study32 kBanonymousapplication/mswordf08-autoimmune-profile 
03.08.26A new biomarker in Huntington's disease32 kBanonymousapplication/mswordf15-new-biomarker 

Le dossier contient 13 documents.
about us | privacy statement | disclaimer | terms of use